3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
19
Breast Neoplasms
12
Neoplasms
8
Multiple Myeloma
8
Melanoma
6
Hematologic Neoplasms
6
Prostatic Neoplasms
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Neoplasm Metastasis
5
Colorectal Neoplasms
5
Carcinoma, Renal Cell
5
Urinary Bladder Neoplasms
4
Thyroid Neoplasms
4
Sarcoma
4
Lung Neoplasms
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Head and Neck Neoplasms
4
Endometrial Neoplasms
4
Adenocarcinoma
4
Thyroid Cancer, Papillary
3
Stomach Neoplasms
3
Salivary Gland Neoplasms
3
Recurrence
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pancreatic Neoplasms
3
Neurofibromatosis 1
3
Neurofibroma, Plexiform
3
Neuroendocrine Tumors
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Mantle-Cell
3
Interventions
belzutifan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Paraganglioma
×
90 days
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA